WallStreetZenWallStreetZen

NASDAQ: BTAI
Bioxcel Therapeutics Inc Stock

$3.21+0.03 (+0.94%)
Updated Mar 1, 2024
BTAI Price
$3.21
Fair Value Price
$3.67
Market Cap
$93.97M
52 Week Low
$1.91
52 Week High
$30.90
P/E
-0.44x
P/B
-2.31x
P/S
59.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.24M
Earnings
-$211.61M
Gross Margin
55.2%
Operating Margin
-15,923.11%
Profit Margin
-17,037.4%
Debt to Equity
-3.47
Operating Cash Flow
-$167M
Beta
1.45
Next Earnings
Mar 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BTAI Overview

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BTAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BTAI ($3.21) is undervalued by 12.54% relative to our estimate of its Fair Value price of $3.67 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BTAI ($3.21) is not significantly undervalued (12.54%) relative to our estimate of its Fair Value price of $3.67 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BTAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BTAI due diligence checks available for Premium users.

Be the first to know about important BTAI news, forecast changes, insider trades & much more!

BTAI News

Valuation

BTAI fair value

Fair Value of BTAI stock based on Discounted Cash Flow (DCF)
Price
$3.21
Fair Value
$3.67
Undervalued by
12.54%
BTAI ($3.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BTAI ($3.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BTAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BTAI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.44x
Industry
15.19x
Market
36.17x

BTAI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-2.31x
Industry
6.18x

BTAI's financial health

Profit margin

Revenue
$341.0k
Net Income
-$50.5M
Profit Margin
-14,805.3%
BTAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BTAI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$100.4M
Liabilities
$141.1M
Debt to equity
-3.47
BTAI's short-term assets ($98.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BTAI's long-term liabilities ($101.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BTAI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BTAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$37.6M
Investing
$0.0
Financing
$0.0
BTAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BTAI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BTAI$93.97M+0.94%-0.44x-2.31x
ACHV$93.55M+9.14%-2.18x23.17x
CUE$95.21M+1.69%-1.76x2.23x
PASG$92.65M-1.17%-0.82x0.73x
VINC$92.58M+15.47%-1.87x5.88x

Bioxcel Therapeutics Stock FAQ

What is Bioxcel Therapeutics's quote symbol?

(NASDAQ: BTAI) Bioxcel Therapeutics trades on the NASDAQ under the ticker symbol BTAI. Bioxcel Therapeutics stock quotes can also be displayed as NASDAQ: BTAI.

If you're new to stock investing, here's how to buy Bioxcel Therapeutics stock.

What is the 52 week high and low for Bioxcel Therapeutics (NASDAQ: BTAI)?

(NASDAQ: BTAI) Bioxcel Therapeutics's 52-week high was $30.90, and its 52-week low was $1.91. It is currently -89.61% from its 52-week high and 68.06% from its 52-week low.

How much is Bioxcel Therapeutics stock worth today?

(NASDAQ: BTAI) Bioxcel Therapeutics currently has 29,272,671 outstanding shares. With Bioxcel Therapeutics stock trading at $3.21 per share, the total value of Bioxcel Therapeutics stock (market capitalization) is $93.97M.

Bioxcel Therapeutics stock was originally listed at a price of $11.03 in Mar 8, 2018. If you had invested in Bioxcel Therapeutics stock at $11.03, your return over the last 5 years would have been -70.9%, for an annualized return of -21.88% (not including any dividends or dividend reinvestments).

How much is Bioxcel Therapeutics's stock price per share?

(NASDAQ: BTAI) Bioxcel Therapeutics stock price per share is $3.21 today (as of Mar 1, 2024).

What is Bioxcel Therapeutics's Market Cap?

(NASDAQ: BTAI) Bioxcel Therapeutics's market cap is $93.97M, as of Mar 2, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bioxcel Therapeutics's market cap is calculated by multiplying BTAI's current stock price of $3.21 by BTAI's total outstanding shares of 29,272,671.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.